ezgif.com-gif-maker.png
Entasis Therapeutics Announces New Results Supporting Advancement of Multiple Pathogen-Targeted Antimicrobial Programs at ASM Microbe 2019
27 juin 2019 08h00 HE | Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., June 27, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel...
DNV3681's exceptional activity against bioterrorist threats presented at ASM Microbe 2019
24 juin 2019 12h00 HE | Deinove
DNV3681's exceptional activity against bioterrorist threats presented at ASM Microbe 2019 Major Steven Zumbrun (USAMRIID1, U.S. Department of Defense) presented data on the in vitro assessment of...
L’activité exceptionnelle du DNV3681 contre des menaces bioterroristes présentée à l’ASM Microbe 2019
24 juin 2019 12h00 HE | Deinove
L’activité exceptionnelle du DNV3681 contre des menaces bioterroristes présentée à l’ASM Microbe 2019 Le Major Steven Zumbrun (USAMRIID1, Département de la Défense des Etats-Unis) a présenté la...
ezgif.com-gif-maker.png
Entasis Therapeutics Announces Oral and Poster Presentations of its Pathogen-Targeted Antibiotic Clinical Programs at ASM Microbe 2019
10 juin 2019 08h00 HE | Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., June 10, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel...